Generated by AI
CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The company’s current work centers on advancing CNS-focused therapeutics designed to address degenerative diseases of the brain, with a lead program built around neflamapimod, an investigational orally administered small molecule intended to act on synaptic dysfunction and related neurodegenerative processes. CervoMed’s pipeline targets conditions such as dementia with Lewy bodies and other disorders affecting cognition and neurological function, reflecting its role in the specialized biopharmaceutical sector. As a public company, CervoMed operates within the broader healthcare innovation market, where clinical development, regulatory progress, and therapeutic differentiation are central to its business model. Headquartered in Boston, Massachusetts, CervoMed Inc. serves as a focused small-cap biotechnology participant developing novel approaches for unmet neurological needs.
Website20 Park Plaza
Boston, MA, 02116
United States
The latest articles about CRVO.
24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage Full 24-week biomarker and clinical data expected in the first quarter of 2027 Nonfluent variant primary progressive aphasia is a rare progressive neurodegenerative brain condition with no approved disease modifying treatments BOSTON, Nov. 16, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) today presented 24-week bioma
Summary of Nov 18's posts. Generated by AI.
Summary of Jul 8's posts. Generated by AI.
Summary of Jun 16's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about CRVO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.